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Background
Ipilimumab blocks the immunologic checkpoint cyto-
toxic T lymphocyte antigen-4 (CTLA-4) and improves
overall survival in patients with metastatic melanoma.
Since only a subset of patients achieves benefit from ipi-
limumab, biomarkers that can predict patient outcome
are needed. CTLA-4 blockade has been shown to affect
the peripheral T cell receptor (TCR) pool, but whether
diversity of the peripheral TCR repertoire is relevant as
a biomarker for ipilimumab remains unknown.
Methods
In this pilot study, we analyzed the baseline (pretreatment)
peripheral blood TCR repertoire in 12 patients with meta-
static melanoma treated with ipilimumab at 3mg/kg
(investigator assessed clinical benefit, n = 4; non-clinical
benefit, n = 8). TCR diversity was evaluated using a multi-
N-plex polymerase chain reaction (PCR) assay which mea-
sures TCR combinatorial diversity between V and J genes
from genomic DNA. The diversity of the TCR pool was
studied through richness (observed V-J rearrangements)
and clonality (evenness of the repertoire based on frequen-
cies of specific V-J rearrangements). The Wilcoxon rank
sum test was used to compare results between patients
with clinical benefit and those without. A receiver operat-
ing characteristic (ROC) curve was used to determine an
appropriate threshold for dichotomized analysis (i.e.
low vs. high diversity richness/clonality). Association with
benefit in the low vs. high groups was assessed through a
Fisher’s exact test. Overall survival was studied through
log-rank analysis.
Results
There was a significant difference in diversity richness
(p = 0.033) and in clonality (p = 0.028) between patients
with and without clinical benefit. Dichotomized analysis
showed that none of the patients with low diversity richness
(n = 0/5, p = 0.081) nor low clonality (n = 0/7, p = 0.01)
achieved clinical benefit. 4 out of the 5 patients with a high
clonality had clinical benefit. There was no significant dif-
ference in overall survival between patients with low vs.
high diversity richness (p = 0.218) and clonality (p = 0.26).
Conclusions
In a small group of melanoma patients treated with ipili-
mumab, TCR diversity in the peripheral blood at baseline
was associated with patient outcomes. Further investiga-
tion is ongoing in larger cohorts of patients treated with
novel immunologic checkpoint antibodies to explore
these preliminary findings and determine whether TCR
diversity can be used as a predictive biomarker in cancer
immunotherapy.
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